Endpoints News

Congruence enters clinic with obesity drug		Read in browser

Thank you for reading, dupa dupackia!

basic

UPGRADE

M T W Thu F

19 March, 2026

AI-driven drug discovery is already reshaping pipelines. But algorithms alone won’t get a drug to the clinic. Join us for a free virtual program — then continue the conversation at an in-person only fireside chat and happy hour in Boston. Reserve your spot.

presented by

5 ways to secure biotech funding in 2026

news

Lilly’s triple-G lags Mounjaro on blood sugar lowering, first Phase 3 diabetes data suggest

Exclusive: Congruence raises $40M, enters clinic with lead obesity drug

House lawmakers signal willingness to counter China’s biotech gains

Mar 24

11:30 am ET

From structure to selectivity: Federated AI for collaborative binding affinity prediction

sponsored by Rhino Federated Computing

The patent cliff is closing in and the dealmaking math has changed fast. Bidding wars, thawing capital markets and a new antitrust environment are all in play — join Drew Armstrong and FT Live for a breakdown on March 18. Register to watch.

endpoints pharma

FDA approves J&J's psoriasis pill Icotyde with $5B+ peak sales potential

FDA seeks to encourage fewer animal studies with new draft guidance

Four major drugmakers will face revived case over 340B prices

FDA opens door to RMAT designations for therapies on clinical hold

in case you missed it

Basecamp debuts an ambitious plan to sequence a trillion genes, but questions remain

Shanghai's Excalipoint gains $68.7M for T cell engagers as founders bet on Chinese system's speed

Briggs Morrison's Crossbow unveils $77M Series B for T cell engagers

Aspen's personalized Parkinson's therapy shows early promise

With its first AI model release, Xaira tests scaling laws in virtual cells

News Briefing

Ionis delays prion disease readout; Arvinas' Parkinson's biomarker data

Obesity Drug Tests Upended by Placebo Patients Quitting Early

Trump Promised the ‘World’s Lowest’ Drug Prices. We Checked the Numbers.

Although Lilly's triple-G candidate did not match Mounjaro in reducing blood sugar levels based on today's results, the company said the investigational drug's overall diabetes and weight loss data so far would still make it attractive to patients if it reaches the market. Read more from Elizabeth Cairns here.

Reynald Castaneda

Deputy Editor, Endpoints News